CN101028362B - 一种治疗白癜风的中成药 - Google Patents
一种治疗白癜风的中成药 Download PDFInfo
- Publication number
- CN101028362B CN101028362B CN200710065481A CN200710065481A CN101028362B CN 101028362 B CN101028362 B CN 101028362B CN 200710065481 A CN200710065481 A CN 200710065481A CN 200710065481 A CN200710065481 A CN 200710065481A CN 101028362 B CN101028362 B CN 101028362B
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- fructus
- herba
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 210000000582 semen Anatomy 0.000 claims description 22
- 241000545442 Radix Species 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- 241001421953 Eclipta <beetle> Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 206010024380 Leukoderma Diseases 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241001446509 Psoralea Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052683 pyrite Inorganic materials 0.000 abstract 1
- 239000011028 pyrite Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 17
- 206010047642 Vitiligo Diseases 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 206010025421 Macule Diseases 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000052 vinegar Substances 0.000 description 5
- 235000021419 vinegar Nutrition 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000201295 Euphrasia Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- -1 electuary Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗白癜风的中成药,它是以沙苑子、白蒺藜、补骨脂、白芷和煅自然铜等14味中草药为原料制成的。本发明是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而成的。本发明的目的是提供一种治疗白癜风的中成药,本发明具有活血通络、消白润肤的功效,治疗和预防白癜风,具有疗效确切,无毒副作用,服用方便,价格低廉的特点。
Description
技术领域
本发明涉及一种治疗白癜风的中成药,是一种治疗白癜风以中草药为原料的中成药。属于中药领域。
背景技术
白癜风是一种后天性局限性色素脱失皮肤病。以皮肤颜色减退,变白,境界鲜明,无自觉症状为特征。与其他色素异常一样,白癜风的发病率随地区、人种肤色而异。一般肤色越深的人发病率越高,我国人群中患病率约在0.1~2%。男女大致相等,从初生婴儿到老年均可发病,但以青少年为多,有资料表明发病年龄在10~30岁组居多,占总数的62.65%,女性发病年龄较男性提早5年左右。
白癜风的临床表现为:任何部位的皮肤均可发生,但好发于易受阳光照射及摩擦损伤部位,如颜面部、颈部、躯干部和四肢等。口唇、阴唇、龟头及包皮内侧黏膜亦可累及。大部分白色斑对称分布、亦有部分患者白斑沿神经节段分布。皮损为局限性色素脱失斑,乳白色,自指甲至钱币大小,圆形、椭圆型或不规则型。白斑处毛发也可变白。在进展期,脱色斑向正常皮肤移行,发展较快,并有同形反应,即压力、摩擦、外伤后可形成继发白癜风。
根据皮肤白斑范围和分布可分三种类型:1、局限型皮损局限于一个部位,又可分为①节段型:皮损按皮节分布;②黏膜型:仅累及黏膜。2、泛发型最常见,表现为皮损广泛分布于体表,可分为①寻常型:皮损散在分布于体表多处;②面肢端型:皮损分布于面部和肢体远端;③混合型:上述几种不同组合而成。如面肢端型+节段型等。3、全身型,全身皮肤完全或几乎全部脱色,亦有毛发变白。
本病相当于中医的白癜、白驳风。如《诸病源候论》白癜记载:“白癜者,面及颈项身体皮肉色变白,与肉不同,亦不痒痛,谓之白癜。”又如《医宗金鉴·外科心示》白驳风记载:“白驳风生面颈间,风邪相搏白点斑甚至遍身,无痒痛,治宜消风涂脂痊。”
中医认为白癜风的发病外因为感受风邪,跌扑损伤;内因为情志内伤,亡血失精等,这些可使气血失和,瘀血阻络,肝肾不足酿成此病。所以中医的治疗是分为气血不和、湿热内蕴、瘀血阻络、肝肾不足、肝郁气滞等症型进行辨证治疗。西医治疗白癜风的方法很多,但大多数只能达到近期临床效果,而不能制止复发,且存在不同程度的毒副作用。
发明内容
本发明是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而成的。本发明的目的是提供一种治疗白癜风的中成药,具有疗效确切、安全方便、无毒副作用、价格低廉的特点。
本发明是由下述重量配比的原料制成的:
沙苑子 2.5~10份 白芷 1.5~6份 白蒺藜 1.5~6份
补骨脂 1.5~6份 苏木 1~4份 鸡血藤 1.5~6份
蛇床子 0.1~2份 浮萍 1~4份 菟丝子 1.5~6份
自鲜皮 1~4份 黄芪 1~4份 墨旱莲 1~4份
煅自然铜 0.1~2份 防风 0.1~2份
本发明的优选配方各原料的重量配比是:
沙苑子 3~7份 白芷 2.5~3.5份 白蒺藜 2.5~3.5份
补骨脂 2.5~3.5份 苏木 1.5~2.5份 鸡血藤 2.5~3.5份
蛇床子 0.1~2份 浮萍 1.5~2.5份 菟丝子 2.5~3.5份
白鲜皮 1.5~2.5份 黄芪 1.5~2.5份 墨旱莲 1.5~2.5份
煅自然铜 0.5~1.5份 防风 0.5~1.5份
本发明的最佳配方各原料的重量配比是:
沙苑子 5份 白芷 3份 白蒺藜 3份
补骨脂 3份 苏木 2份 鸡血藤 3份
蛇床子 1份 浮萍 2份 菟丝子 3份
白鲜皮 2份 黄芪 2份 墨旱莲 2份
煅自然铜 1份 防风 1份
本发明中的药物机理如下:
沙苑子 性味甘,温。归肝、肾经。具有温补肝肾,固精,缩尿,明目的功效。可治疗肾虚腰痛,遗精早泄,自浊带下,小便余沥,眩晕目昏等。(国家药典委员会编《中华人民共和国药典》2000年版一部 第145页 化学工业出版社)。
白蒺藜 性味辛、苦,微温;有小毒。归肝经。具有平肝解郁,活血祛风,明目,止痒的功效。可治疗头痛眩晕,胸胁胀痛,乳闭乳痈,目赤翳障,风疹瘙痒等。(国家药典委员会编《中华人民共和国药典》2000年版一部第289页 化学工业出版社)。
补骨脂 性味辛、苦,温。归肾、脾经。具有补肾壮阳,固精缩尿,温脾止泻,纳气的功效。可治疗骨肉瘤、肿瘤骨转移、化疗放疗后白细胞减少、出血性疾患、白癜风、肾虚冷泻、遗尿、滑精、小便频数、阳痿、腰膝冷痛、尿频、虚寒喘嗽等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第714页)。
白芷 性味辛,温。归胃、大肠、肺经。具有散风除湿,通窍止痛,消肿排脓的功效。可治疗感冒头痛,眉棱骨痛,鼻塞,鼻渊,牙痛,白带,疮疡肿痛等。(国家药典委员会编《中华人民共和国药典》2000年版一部第79页 化学工业出版社)。
苏木 性味甘、咸,平。归心、肝、脾经。具有行血祛瘀,消肿止痛的功效。可治疗经闭痛经,产后瘀阻,胸腹刺痛,外伤肿痛等。(国家药典委员会编《中华人民共和国药典》2000年版一部第130页 化学工业出版社)。
浮萍 药性 辛,寒。归肺、膀胱经。具有发汗解表,利水消肿,清热解毒的功效。可治疗风热表证,麻疹不透,隐疹瘙痒,水肿,癃闭,疮癣,丹毒,烫伤等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第2765页)。
鸡血藤 性味苦、甘、温。归肝、肾经。具有补血、活血,通络的功效。可治疗月经不调,血虚萎黄,麻木瘫痪,风湿痹痛等。(国家药典委员会编《中华人民共和国药典》2000年版一部 第151页 化学工业出版社)。
蛇床子 药性 辛、苦,温。归肝、肾经。具有温肾壮阳,燥湿杀虫,祛风止痒的功效。可治疗男子阳痿,女子宫寒不孕,湿痹腰痛,寒湿带下,阴囊湿痒,风湿痹痛,湿疮,疥癣等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第3005页)。
黄芪 性味甘、温。归肺、脾经。具有益卫固表,利水消肿,托毒,生肌的功效。用于内伤劳倦、脾虚泄泻、脱肛、气虚血脱、崩带、自汗、盗汗、血痹、浮肿、痈疽不溃或溃之不敛及一切气衰血虚之症。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第1074页)。
菟丝子 性味辛、甘、温、平。归肝、肾、脾经。具有补肝肾、益精髓、明目益精的功效。可治疗胃癌、骨癌、肺癌、鼻咽癌、腰膝酸痛、阳痿遗精、消渴、尿有余沥、目暗、头昏目眩、视力减退、胎动不安、尿频等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版 第1066页)。
白鲜皮 性味苦、寒。归脾、胃、膀胱经。具有清热燥湿,祛风解毒的功效。可治疗湿热疮毒,黄水淋漓,湿疹,风疹,疥癣疮癞,风湿热痹,黄疸尿赤等。(国家药典委员会编《中华人民共和国药典》2000年版一部 第83页 化学工业出版社)。
墨旱莲 药性 甘、酸,凉。归肝、肾经。具有补益肝肾,凉血止血。可治疗肝肾不足,头晕目眩,须发早白,吐血,咯血,衄血,便血,血痢,崩漏,外伤出血等。(《中药大辞典》南京中医药大学 编著上海科学技术出版社 第二版 第3690页)。
防风 性味辛、甘,温。归膀胱、肝、脾经。具有解表祛风,胜湿,止痉的功效。可治疗感冒头痛,风湿痹痛,风疹瘙痒,破伤风等。(国家药典委员会编《中华人民共和国药典》2000年版一部 第117页 化学工业出版社)。
醋自然铜 药性 辛,平。归肝、肾经。具有散瘀止痛,续筋接骨的功效。可治疗跌打损伤,筋断骨折,瘀滞肿痛等。(《中药大辞典》南京中医药大学编著上海科学技术出版社 第二版 第1273页)。
本发明遵循中医“君臣佐使”的组方原则,用沙苑子、白蒺藜、补骨脂和白芷为君药,用苏木、浮萍、鸡血藤、蛇床子、黄芪、菟丝子、白藓皮和墨旱莲为臣药,防风和醋自然铜为佐使药。诸药相和共具有活血通络、消白润肤的功效,治疗和预防白癜风,疗效确切,无毒副作用,服用方便,价格低廉。
本发明的中药制剂,在制备成药剂时可加入药物可接受的载体,所述药物可接受的载体可以是:淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素类及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的中药制剂可以是任何可药用的剂型,这些剂型包括:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含片颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂。本发明的制剂,优选的是口服剂型,如:片剂、胶囊剂、口服液、口含片、颗粒剂、冲剂、丸剂、散剂、混悬剂、粉剂、溶液剂、滴剂、滴丸剂。更优选的中药制剂是胶囊剂、片剂、颗粒剂。
本发明药物临床使用结果表明,有如下优点:
1、本发明选用的中草药各组份符合中华人民共和国药品管理法之规定,利用各味中药的综合作用治疗和预防白癜风,对人体无毒无害。经动物急性毒性实验表明被实验的动物未见任何毒性反应,其主要脏器也无明显的改变,药物安全可靠。
2、本发明无须煎煮,无苦涩感,药中富含蛋白质,葡萄糖,葡萄糖醛酸,挥发油,果胶,果糖,有机酸,卵磷脂,维生素,氨基酸,还含皂甙,植物甾醇和钙等多种微量元素,利于人体吸收,增强体质,且服用方便。
3、本发明不仅可有效的治疗白癜风,对白癜风的预防也有很好的作用,大大提高了患者的生存质量,有较高的治愈康复效果。
下面通过临床应用例进一步说明本发明药物对治疗白癜风的治疗效果。
白癜风疗效判定标准(陈勤主编《中药美容保健品的研究与开发》中国医药科技出版社1999年版第228页。)
(1)痊愈:白斑完全消失,皮肤组织病理学检查正常。
(2)显效:白斑50%以上消失,白斑消失部分组织病理学检查正常。
(3)有效:白斑消失者占原白斑面积的20%~50%,或在白斑内见有较多色素岛。
(4)无效:治疗前后无变化或自斑扩大。
经临床试验结果如下;治疗白癜风患者88例,男性40例,女性48例,年龄为10~45岁。服用实施例1胶囊剂,每次2-10粒,每日三至四次,温开水送下,饭前半小时服用。两个月为一个疗程,连续服用三个疗程观察疗效。痊愈75例占85%,显效6例占6.8%,有效5例占5.6%,无效2例占2.2%,总有效率达97%以上。经三个疗程治疗后,患者皮肤白斑不同程度消退或痊愈。且病人无任何不良反应,三大常规化验及肝肾功能检测未发现异常。
具体实施方式
实施例1 胶囊剂 按下述重量称取原料:
沙苑子 5份 白芷 3份 白蒺藜 3份
补骨脂 3份 苏木 2份 鸡血藤 3份
蛇床子 1份 浮萍 2份 菟丝子 3份
白鲜皮 2份 黄芪 2份 墨旱连 2份
醋自然铜 1份 防风 1份
制备方法是上述原料加水煎煮两次,第一次1.5~2小时,第二次0.5~1小时,合并两次煎液,滤过,滤液浓缩至80度~85度时,相对密度1.08~1.10的清膏,加入乙醇使清膏含醇量达70%,静置24小时,回收乙醇,在50度~55度时浓缩至相对密度1.30~1.32的清膏,干燥,粉碎成细粉,装入胶囊。每粒装0.3克,通常饭前半小时口服,温开水送下,一次2~10粒,一日三至四次,两个月为一个疗程。
实施例2 片剂 按下述重量称取原料:
沙苑子 5份 白芷 3份 白蒺藜 3份
补骨脂 3份 苏木 2份 鸡血藤 3份
蛇床子 1份 浮萍 2份 菟丝子 3份
白鲜皮 2份 黄芪 2份 墨旱连 2份
醋自然铜 1份 防风 1份
制备方法是取上述原料加水煎煮两次,第一次1.5~2小时,第二次0.5~1小时,合并两次煎液,滤过,滤液浓缩至80度~85度时,相对密度1.08~1.10的清膏,加入乙醇使清膏含醇量达70%,静置24小时,回收乙醇,在50度~55度时浓缩至相对密度1.30~1.32的清膏,干燥,粉碎成细粉,加入适量淀粉、乙醇制粒,干燥后,加入适量硬脂酸镁,压片,包糖衣即得。通常饭前半小时口服,温开水送下,一次2~10片,一日三至四次,两个月为一个疗程。
实施例3 颗粒剂 按下述重量称取原料:
沙苑子 5份 白芷 3份 白蒺藜 3份
补骨脂 3份 苏木 2份 鸡血藤 3份
蛇床子 1份 浮萍 2份 菟丝子 3份
白鲜皮 2份 黄芪 2份 墨旱连 2份
醋自然铜 1份 防风 1份
制备方法是取上述原料加水煎煮两次,第一次1.5~2小时,第二次0.5~1小时,合并两次煎液,滤过,滤液浓缩至80度~85度时,相对密度1.08~1.10的清膏,加入乙醇使清膏含醇量达70%,静置24小时,回收乙醇,在50度~55度时浓缩至相对密度1.30~1.32的清膏,干燥,粉碎成细粉,加入适量蔗糖和可溶性淀粉,乙醇制粒,干燥后装袋即得。通常饭前半小时温开水冲服,一次1~3袋,一日三至四次,两个月为一个疗程。
Claims (3)
1.一种治疗白癜风的中成药,其特征在于它是由下述重量配比的原料药制成的:
沙苑子2.5~10份 白芷1.5~6份 白蒺藜1.5~6份
补骨脂1.5~6份 苏木1~4份 鸡血藤1.5~6份
蛇床子0.1~2份 浮萍1~4份 菟丝子1.5~6份
白鲜皮1~4份 黄芪1~4份 墨旱莲1~4份
煅自然铜0.1~2份 防风0.1~2份。
2.根据权利要求1所述的一种治疗白癜风的中成药,其中各原料药的重量配比是:
沙苑子3~7份 白芷2.5~3.5份 白蒺藜2.5~3.5份
补骨脂2.5~3.5份 苏木1.5~2.5份 鸡血藤2.5~3.5份
蛇床子0.1~2份 浮萍1.5~2.5份 菟丝子2.5~3.5份
白鲜皮1.5~2.5份 黄芪1.5~2.5份 墨旱莲1.5~2.5份
煅自然铜0.5~1.5份 防风0.5~1.5份。
3.根据权利要求1所述的一种治疗白癜风的中成药,其中各原料药的重量配比是:
沙苑子5份 白芷3份 白蒺藜3份
补骨脂3份 苏木2份 鸡血藤3份
蛇床子1份 浮萍2份 菟丝子3份
白鲜皮2份 黄芪2份 墨旱莲2份
煅自然铜1份 防风1份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710065481A CN101028362B (zh) | 2007-04-16 | 2007-04-16 | 一种治疗白癜风的中成药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710065481A CN101028362B (zh) | 2007-04-16 | 2007-04-16 | 一种治疗白癜风的中成药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101028362A CN101028362A (zh) | 2007-09-05 |
CN101028362B true CN101028362B (zh) | 2010-05-19 |
Family
ID=38714014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710065481A Expired - Fee Related CN101028362B (zh) | 2007-04-16 | 2007-04-16 | 一种治疗白癜风的中成药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101028362B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191368B (zh) * | 2013-03-31 | 2014-03-12 | 张秀兰 | 一种治疗白癜风的药物及其制备方法 |
CN104189682A (zh) * | 2014-09-19 | 2014-12-10 | 葛文涛 | 一种治疗白癜风的中药制剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1082907A (zh) * | 1992-12-11 | 1994-03-02 | 张才 | 白癜风丸 |
CN1177489A (zh) * | 1997-09-02 | 1998-04-01 | 史培明 | 医治白癜风的中药及其配制方法 |
-
2007
- 2007-04-16 CN CN200710065481A patent/CN101028362B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1082907A (zh) * | 1992-12-11 | 1994-03-02 | 张才 | 白癜风丸 |
CN1177489A (zh) * | 1997-09-02 | 1998-04-01 | 史培明 | 医治白癜风的中药及其配制方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101028362A (zh) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100473413C (zh) | 一种治疗老年期痴呆的中药制剂 | |
CN102416079A (zh) | 一种治疗白癜风的中成药 | |
CN100571736C (zh) | 一种治疗习惯性流产的中药制剂 | |
CN100496585C (zh) | 一种治疗黄褐斑的中药制剂 | |
CN103705751B (zh) | 用于治疗风湿腰痛的中药组合物及其制备方法 | |
CN102362950A (zh) | 一种治疗白癜风的中药 | |
CN101897933B (zh) | 一种治疗白癜风的中成药 | |
CN101028362B (zh) | 一种治疗白癜风的中成药 | |
CN102430013A (zh) | 治疗白癜风的中药 | |
CN102727648A (zh) | 一种治疗白癜风的中药组合物 | |
CN100450531C (zh) | 一种治疗小儿遗尿的中药制剂 | |
CN100431578C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN100415288C (zh) | 一种治疗银屑病的中药制剂 | |
CN101049370A (zh) | 一种治疗白癜风的中药制剂 | |
CN100546635C (zh) | 一种治疗白癜风的中药制剂 | |
CN100546607C (zh) | 一种治疗白癜风的中药制剂 | |
CN102406865A (zh) | 一种治疗银屑病的中药组合物 | |
CN100415289C (zh) | 一种治疗白癜风的中药制剂 | |
CN100571725C (zh) | 一种治疗坐骨神经痛的中药制剂 | |
CN100394948C (zh) | 一种治疗白癜风的中药制剂 | |
CN100450537C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN101028421B (zh) | 一种治疗慢性肾衰的中成药 | |
CN109674974A (zh) | 一种补肾固精养元膏药及其制备方法 | |
CN100571743C (zh) | 一种治疗阳痿的中药制剂 | |
CN100415276C (zh) | 一种治疗白癜风的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20110416 |